治疗初级节点阳性前列腺癌:对可用的治疗选择进行全面审查
Lotte G Zuur1, Hilda A de Barros1, Koen J C van der Mijn2
1Department of Surgical Oncology (Urology), Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
Cancers
|June 10, 2023
概括
对节点阳性激素敏感前列腺癌 (PCa) 的最佳治疗正在发展. 强化治疗,包括雄激素剥夺疗法和放射治疗,对cN1M0和pN1M0PCa的潜在可治愈患者来说是有前途的.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 在瘤学瘤学.
- 辐射瘤学 辐射瘤学
背景情况:
- 对于节点阳性激素敏感前列腺癌 (PCa) 的最佳治疗方法缺乏共识.
- 研究表明,加强治疗可能为这些患者提供治愈潜力.
- 本综述涉及临床和病理结节阳性 (cN1M0和pN1M0) PCa.的治疗选择.
研究的目的:
- 为cN1M0和pN1M0激素敏感前列腺癌提供当前治疗策略的概述.
- 综合结点阳性PCa治疗结果的证据.
- 确定需要进一步研究的领域.
主要方法:
- 2002年至2022年间发表的Medline指数化研究的范围审查.
- 包括随机对照试验,系统审查和回顾性/观察性研究.
- 专注于cN1M0和pN1M0PCa患者的治疗方法和结果.
主要成果:
- 对于cN1M0 PCa,已经确立了与前列腺和淋巴结结合的雄激素剥夺疗法 (ADT) 和外部束辐射疗法 (EBRT).
- 强化治疗可能有利于cN1M0患者,但需要更多的随机数据.
- 对于pN1M0PCa,根据格里森得分,阶段和结节状况推风险分层辅助或救援疗法 (监测,ADT,EBRT).
结论:
- 对于cN1M0和pN1M0PCa存在既定的治疗方法,并且正在向强化方向发展.
- 进一步的随机试验至关重要,以证实对cN1M0 PCa.加强治疗的益处.
- 风险分层指导pN1M0PCa患者的辅助/救援治疗决策.
相关概念视频
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
02:49Cancer Therapies
7.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.8K